nanoluc binary (nanobit) split luciferase (Promega)
90
Structured Review
Promega
nanoluc binary (nanobit) split luciferase
Nanoluc Binary (Nanobit) Split Luciferase, supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/binary/nanoluc+binary++nanobit++split+luciferase/pmc11861568-167-9-3
Average 90 stars, based on 1 article reviews
Nanoluc Binary (Nanobit) Split Luciferase, supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/binary/nanoluc+binary++nanobit++split+luciferase/pmc11861568-167-9-3
Average 90 stars, based on 1 article reviews
nanoluc binary (nanobit) split luciferase - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Luciferase:Article Title: In Silico and In Cell Hybrid Selection of Nonrapalog Ligands to Allosterically Inhibit the Kinase Activity of mTORC1. Article Snippet: Cancer-specific metabolic alterations hyperactivate the kinase activity of the mammalian/mechanistic target of rapamycin (mTOR) for overcoming stressful environments.. Rapalogs, which allosterically inhibit mTOR complex 1 (mTORC1), have been approved as anticancer agents.. However, the immunosuppressive side effect of these compounds results in the promotion of tumor metastasis, thereby limiting their therapeutic efficacy. Protein-Protein interactions:Article Title: In Silico and In Cell Hybrid Selection of Nonrapalog Ligands to Allosterically Inhibit the Kinase Activity of mTORC1. Article Snippet: Cancer-specific metabolic alterations hyperactivate the kinase activity of the mammalian/mechanistic target of rapamycin (mTOR) for overcoming stressful environments.. Rapalogs, which allosterically inhibit mTOR complex 1 (mTORC1), have been approved as anticancer agents.. However, the immunosuppressive side effect of these compounds results in the promotion of tumor metastasis, thereby limiting their therapeutic efficacy. Incubation:Article Title: In Silico and In Cell Hybrid Selection of Nonrapalog Ligands to Allosterically Inhibit the Kinase Activity of mTORC1. Article Snippet: Cancer-specific metabolic alterations hyperactivate the kinase activity of the mammalian/mechanistic target of rapamycin (mTOR) for overcoming stressful environments.. Rapalogs, which allosterically inhibit mTOR complex 1 (mTORC1), have been approved as anticancer agents.. However, the immunosuppressive side effect of these compounds results in the promotion of tumor metastasis, thereby limiting their therapeutic efficacy. other:Article Title: Luminescent sensing of conformational integrin activation in living cells. Article Snippet: We selected the Article Title: Luminescent sensing of conformational integrin activation in living cells Article Snippet: We selected the |